

CPM PROTEINS LIMITED
Abridged Unaudited Financial Statements
for the financial year ended 31 October 2025

CPM PROTEINS LIMITED

CONTENTS

	Page
Director's Responsibilities Statement	3
Balance Sheet	4
Reconciliation of Shareholders' Funds	5
Notes to the Financial Statements	6 - 10

CPM PROTEINS LIMITED

DIRECTOR'S RESPONSIBILITIES STATEMENT

for the financial year ended 31 October 2025

The director is responsible for preparing the Director's Report and the financial statements in accordance with applicable Irish law and regulations.

Irish company law requires the director to prepare financial statements for each financial year. Under that law, the director have elected to prepare the financial statements in accordance with the Companies Act 2014 and FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" issued by the Financial Reporting Council. Under company law, the director must not approve the financial statements unless they is satisfied that they give a true and fair view of the assets, liabilities and financial position of the company as at the financial year end date and of the profit or loss of the company for the financial year and otherwise comply with the Companies Act 2014.

In preparing these financial statements, the director is required to:

- select suitable accounting policies for the company financial statements and then apply them consistently;
- make judgements and accounting estimates that are reasonable and prudent;
- state whether the financial statements have been prepared in accordance with applicable accounting standards, identify those standards, and note the effect and the reasons for any material departure from those standards; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business.

The director is responsible for ensuring that the company keeps or causes to be kept adequate accounting records which correctly explain and record the transactions of the company, enable at any time the assets, liabilities, financial position and profit or loss of the company to be determined with reasonable accuracy, enable them to ensure that the financial statements and Director's Report comply with the Companies Act 2014. They is also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Signed on behalf of the board

Christopher Meaney
Director

19 December 2025

CPM PROTEINS LIMITED

BALANCE SHEET

as at 31 October 2025

	Notes	2025 €	2024 €
Fixed Assets			
Tangible assets	7	639,847	647,749
Investments	8	267,500	267,500
Fixed Assets		907,347	915,249
Current Assets			
Stocks	9	-	61,608
Debtors	10	728,850	554,777
Cash and cash equivalents		672,801	347,856
		1,401,651	964,241
Creditors: amounts falling due within one year	11	(328,394)	(292,737)
Net Current Assets		1,073,257	671,504
Total Assets less Current Liabilities		1,980,604	1,586,753
Creditors: amounts falling due after more than one year	12	(141,283)	(189,024)
Net Assets		1,839,321	1,397,729
Capital and Reserves			
Called up share capital presented as equity		10	10
Retained earnings		1,839,311	1,397,719
Equity attributable to owners of the company		1,839,321	1,397,729

We as Director's of CPM PROTEINS LIMITED, state that -

(a) the company is availing itself of the exemption provided for by Chapter 15 of Part 6 of the Companies Act 2014,

(b) the company is availing itself of the exemption on the grounds that the conditions specified in section 358 are satisfied,

(c) the shareholders of the company have not served a notice on the company under section 334(1) in accordance with section 334(2),

(d) we acknowledge the company's obligations under the Companies Act 2014, to keep adequate accounting records and prepare financial statements which give a true and fair view of the assets, liabilities and financial position of the company at the end of its financial year and of its profit or loss for such a financial year and to otherwise comply with the provisions of the Companies Act 2014 relating to financial statements so far as they are applicable to the company,

(e) the company has relied on the specified exemption contained in section 352 Companies Act 2014. The company has done so on the grounds that the company is entitled to the benefit of that exemption as a small company and the abridged financial statements have been properly prepared in accordance with section 353 Companies Act 2014 and the small companies' regime.

Approved by the board on 19 December 2025 and signed on its behalf by:

Christopher Meaney
Director

CPM PROTEINS LIMITED

RECONCILIATION OF SHAREHOLDERS' FUNDS

as at 31 October 2025

	Called up share capital €	Retained earnings €	Total €
At 1 November 2023	10	1,065,327	1,065,337
Profit for the financial year	-	332,392	332,392
At 31 October 2024	10	1,397,719	1,397,729
Profit for the financial year	-	441,592	441,592
At 31 October 2025	10	1,839,311	1,839,321

CPM PROTEINS LIMITED

NOTES TO THE ABRIDGED FINANCIAL STATEMENTS

for the financial year ended 31 October 2025

1. General Information

CPM PROTEINS LIMITED is a company limited by shares incorporated and registered in Ireland. The registered number of the company is 591762. The registered office of the company is. The principal activity of the company is the purchase, sale and export of agri food products. The financial statements have been presented in Euro (€) which is also the functional currency of the company.

2. Summary of Significant Accounting Policies

The following accounting policies have been applied consistently in dealing with items which are considered material in relation to the company's financial statements.

Statement of compliance

The financial statements of the company for the financial year ended 31 October 2025 have been prepared on the going concern basis and in accordance with FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" (FRS 102).

Basis of preparation

The financial statements have been prepared on the going concern basis and in accordance with the historical cost convention except for certain properties and financial instruments that are measured at revalued amounts or fair values, as explained in the accounting policies below. Historical cost is generally based on the fair value of the consideration given in exchange for assets. The financial reporting framework that has been applied in their preparation is the Companies Act 2014 and FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" issued by the Financial Reporting Council.

The company qualifies as a small company as defined by section 280A of the Companies Act 2014 in respect of the financial year, and has applied the rules of the 'Small Companies Regime' in accordance with section 280C of the Companies Act 2014.

Cash flow statement

The company has availed of the exemption in FRS 102 from the requirement to prepare a Cash Flow Statement because it is classified as a small company.

Turnover

Turnover comprises the invoice value of goods supplied by the company, exclusive of trade discounts and value added tax.

Tangible assets and depreciation

Tangible assets are stated at cost or at valuation, less accumulated depreciation. The charge to depreciation is calculated to write off the original cost or valuation of tangible assets, less their estimated residual value, over their expected useful lives as follows:

Land and buildings freehold	-	4% Straight line
Fixtures, fittings and equipment	-	12.5% Straight line

The carrying values of tangible fixed assets are reviewed annually for impairment in periods if events or changes in circumstances indicate the carrying value may not be recoverable.

Leasing and hire purchases

Tangible assets held under leasing and Hire Purchases arrangements which transfer substantially all the risks and rewards of ownership to the company are capitalised and included in the Balance Sheet at their cost or valuation, less depreciation. The corresponding commitments are recorded as liabilities. Payments in respect of these obligations are treated as consisting of capital and interest elements, with interest charged to the Profit and Loss Account.

Investments

Investments held as fixed assets are stated at cost less provision for any permanent diminution in value. Income from other investments together with any related withholding tax is recognised in the Profit and Loss Account in the financial year in which it is receivable.

CPM PROTEINS LIMITED

NOTES TO THE ABRIDGED FINANCIAL STATEMENTS

for the financial year ended 31 October 2025

Stocks

Stocks are valued at the lower of cost and net realisable value. Stocks are determined on a first-in first-out basis. Cost comprises expenditure incurred in the normal course of business in bringing stocks to their present location and condition. Full provision is made for obsolete and slow moving items. Net realisable value comprises actual or estimated selling price (net of trade discounts) less all further costs to completion or to be incurred in marketing and selling.

Trade and other debtors

Trade and other debtors are initially recognised at fair value and thereafter stated at amortised cost using the effective interest method less impairment losses for bad and doubtful debts except where the effect of discounting would be immaterial. In such cases the receivables are stated at cost less impairment losses for bad and doubtful debts.

Borrowing costs

Borrowing costs relating to the acquisition of assets are capitalised at the appropriate rate by adding them to the cost of assets being acquired. Investment income earned on the temporary investment of specific borrowings pending their expenditure on the assets is deducted from the borrowing costs eligible for capitalisation. All other borrowing costs are recognised in profit or loss in the period in which they are incurred.

Trade and other creditors

Trade and other creditors are initially recognised at fair value and thereafter stated at amortised cost using the effective interest rate method, unless the effect of discounting would be immaterial, in which case they are stated at cost.

Employee benefits

The company operates a defined contribution pension scheme. The assets of the scheme are held separately from those of the company in an independently administered fund. The company also operates a defined benefit pension scheme for its employees providing benefits based on final pensionable pay. The assets of this scheme are also held separately from those of the company, being invested with pension fund managers.

Taxation and deferred taxation

Current tax represents the amount expected to be paid or recovered in respect of taxable profits for the financial year and is calculated using the tax rates and laws that have been enacted or substantially enacted at the Balance Sheet date.

Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date where transactions or events have occurred at that date that will result in an obligation to pay more tax in the future, or a right to pay less tax in the future. Timing differences are temporary differences between the company's taxable profits and its results as stated in the financial statements.

Deferred tax is measured on an undiscounted basis at the tax rates that are anticipated to apply in the periods in which the timing differences are expected to reverse, based on tax rates and laws that have been enacted or substantively enacted by the Balance Sheet date.

Foreign currencies

Monetary assets and liabilities denominated in foreign currencies are translated at the rates of exchange ruling at the Balance Sheet date. Non-monetary items that are measured in terms of historical cost in a foreign currency are translated at the rates of exchange ruling at the date of the transaction. Non-monetary items that are measured at fair value in a foreign currency are translated using the exchange rates at the date when the fair value was determined. The resulting exchange differences are dealt with in the Profit and Loss Account.

Ordinary share capital

The ordinary share capital of the company is presented as equity.

3. Operating profit	2025	2024
	€	€
Operating profit is stated after charging/(crediting):		
Depreciation of tangible assets	127,666	113,027
Profit on foreign currencies	-	(673)
	=====	=====

CPM PROTEINS LIMITED
NOTES TO THE ABRIDGED FINANCIAL STATEMENTS

for the financial year ended 31 October 2025

4. Interest payable and similar expenses	2025	2024
	€	€
Interest	<u>24,645</u>	<u>24,461</u>
5. Employees		
The average monthly number of employees, including director, during the financial year was 2, (2024 - 2).		
	2025	2024
	Number	Number
General	<u>2</u>	<u>2</u>
6. Tax on profit	2025	2024
	€	€
(a) Analysis of charge in the financial year		
Current tax:		
Corporation tax at 12.50% (2024 - 12.50%) (Note 6 (b))	<u>63,116</u>	<u>47,485</u>
(b) Factors affecting tax charge for the financial year		
The tax assessed for the financial year differs from the standard rate of corporation tax in the Republic of Ireland 12.50% (2024 - 12.50%). The differences are explained below:		
	2025	2024
	€	€
Profit taxable at 12.50%	<u>504,708</u>	<u>379,877</u>
Profit before tax multiplied by the standard rate of corporation tax in the Republic of Ireland at 12.50% (2024 - 12.50%)	63,089	47,485
Effects of:		
Expenses not deductible for tax purposes	<u>27</u>	-
Total tax charge for the financial year (Note 6 (a))	<u>63,116</u>	<u>47,485</u>

CPM PROTEINS LIMITED
NOTES TO THE ABRIDGED FINANCIAL STATEMENTS

for the financial year ended 31 October 2025

7. Tangible assets

	Land and buildings freehold €	Fixtures, fittings and equipment €	Total €
Cost			
At 1 November 2024	26,738	907,576	934,314
Additions	2,643	117,121	119,764
At 31 October 2025	<u>29,381</u>	<u>1,024,697</u>	<u>1,054,078</u>
Depreciation			
At 1 November 2024	-	286,565	286,565
Charge for the financial year	-	127,666	127,666
At 31 October 2025	<u>-</u>	<u>414,231</u>	<u>414,231</u>
Net book value			
At 31 October 2025	<u>29,381</u>	<u>610,466</u>	<u>639,847</u>
At 31 October 2024	<u>26,738</u>	<u>621,011</u>	<u>647,749</u>

8. Investments

	Other unlisted investments €	Total €
Investments		
Cost		
At 31 October 2025	<u>267,500</u>	<u>267,500</u>
Net book value		
At 31 October 2025	<u>267,500</u>	<u>267,500</u>
At 31 October 2024	<u>267,500</u>	<u>267,500</u>

9. Stocks

	2025 €	2024 €
Finished goods and goods for resale	<u>-</u>	<u>61,608</u>

The replacement cost of stock did not differ significantly from the figures shown.

10. Debtors

	2025 €	2024 €
Trade debtors	<u>728,850</u>	<u>554,777</u>

11. Creditors

	2025 €	2024 €
Amounts falling due within one year		
Net obligations under finance leases and hire purchase contracts	104,060	162,603
Trade creditors	138,698	64,522
Taxation	81,902	61,513
Director's current account (Note 15)	3,734	4,099
	<u>328,394</u>	<u>292,737</u>

CPM PROTEINS LIMITED
NOTES TO THE ABRIDGED FINANCIAL STATEMENTS

for the financial year ended 31 October 2025

12. Creditors	2025	2024
Amounts falling due after more than one year	€	€
Bank loan	<u>141,283</u>	<u>189,024</u>
Loans		
Repayable between one and two years	<u>120,216</u>	120,216
Repayable between two and five years	<u>21,067</u>	68,808
	<u>141,283</u>	<u>189,024</u>

13. Income Statement

	2025	2024
	€	€
At 1 November 2024	<u>1,397,719</u>	1,065,327
Profit for the financial year	<u>441,592</u>	332,392
At 31 October 2025	<u>1,839,311</u>	<u>1,397,719</u>

14. Capital commitments

The company had no material capital commitments at the financial year-ended 31 October 2025.

15. Director's remuneration and transactions	2025	2024
	€	€
Remuneration	<u>48,667</u>	<u>41,667</u>

16. Post-Balance Sheet Events

There have been no significant events affecting the company since the financial year-end.

17. Approval of financial statements

The financial statements were approved and authorised for issue by the board on 19 December 2025.